ABVCABVC BIOPHARMA, INC.同业对比
ABVC BIOPHARMA, INC. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABVC本股 | $31M#8 | — | 3.0x#10 | 104.0x#8 | 0.0%#4 | -61.3%#12 | -2416.0%#8 | -76.9%#5 | -68.5%#5 | — | -59.9%#11 | — |
| FLNA | $34M#2 | — | 0.5x#2 | 0.8x#2 | 277.6%#1 | -273.7%#14 | -232.0%#4 | -133.5%#12 | — | — | -66.4%#13 | — |
| CNTX | $34M#1 | — | 0.9x#5 | — | — | -35.2%#10 | — | -94.6%#6 | — | — | -57.5%#10 | — |
| RMTI | $32M#3 | 267.0x#2 | 0.9x#7 | 0.5x#1 | -31.8%#7 | -1007.1%#16 | -6.8%#1 | -15.1%#4 | -14.0%#4 | 4#3 | -52.3%#9 | — |
| CPHI | $31M#4 | — | 0.9x#4 | 7.5x#5 | -8.5%#6 | 32.7%#5 | -78.2%#2 | -8.8%#3 | -7.7%#2 | 5#1 | -63.2%#12 | — |
| BRNS | $31M#5 | — | 0.5x#3 | — | -100.0%#10 | -8.8%#7 | — | -116.4%#9 | — | — | -37.0%#6 | — |
| KYNB | $31M#6 | 0.2x#1 | — | 4.8x#4 | -78.3%#8 | 485.6%#1 | -712.7%#7 | — | — | — | -37.9%#7 | — |
| RNAZ | $31M#7 | — | — | — | — | -106.9%#13 | — | — | — | — | -83.9%#15 | — |
| MIRA | $30M#9 | — | 3.7x#12 | — | — | -33.0%#9 | — | -127.9%#10 | — | — | -45.1%#8 | — |
| NNVC | $29M#10 | — | 3.2x#11 | — | — | -14.1%#8 | — | -103.4%#7 | -89.9%#6 | — | -6.6%#3 | — |
| IGC | $28M#12 | — | 4.6x#13 | 22.2x#7 | -5.5%#5 | 45.2%#3 | -585.8%#6 | -116.1%#8 | -125.5%#7 | 3#4 | -33.7%#5 | — |
| HEPA | $29M#11 | — | 22.4x#14 | — | — | 37.3%#4 | — | -647.5%#14 | — | — | -17.6%#4 | — |
| APUS | $3M#16 | — | 0.0x#1 | — | — | -331.7%#15 | — | -5.6%#2 | -11.2%#3 | — | -89.4%#16 | — |
| NXTC | $27M#13 | — | 2.3x#9 | 1.2x#3 | 252.6%#2 | -0.3%#6 | -257.5%#5 | -459.7%#13 | — | — | 4.6%#2 | — |
| TXMD | $25M#14 | — | 0.9x#8 | 8.4x#6 | 71.6%#3 | 73.9%#2 | -145.3%#3 | -2.1%#1 | -3.8%#1 | 5#1 | 93.8%#1 | — |
| ATOS | $25M#15 | — | 0.9x#6 | 13992.6x#9 | -95.6%#9 | -36.3%#11 | -2112684.9%#9 | -129.6%#11 | — | — | -79.9%#14 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议